LONDON/BOSTON, Oct 15 (Reuters) - Biogen Idec Inc (BIIB.O: Quote, Profile, Research), which has put itself up for sale, may get bids of around $25-30 billion from several of the world’s top drugmakers keen to expand in the hot area of biotech medicine.
